Cargando…

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis

BACKGROUND AND OBJECTIVES: The specificity of novel blood biomarkers for multiple sclerosis (MS)–related neurodegeneration is unclear because neurodegeneration also occurs during normal aging. To understand which aspects of neurodegeneration the serum biomarkers neurofilament light (sNfL), serum gli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loonstra, Floor C., de Ruiter, Lodewijk R.J., Koel-Simmelink, Marleen J.A., Schoonheim, Menno M., Strijbis, Eva M.M., Moraal, Bastiaan, Barkhof, Frederik, Uitdehaag, Bernard M.J., Teunissen, Charlotte, Killestein, Joep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773420/ https://www.ncbi.nlm.nih.gov/pubmed/36543540 http://dx.doi.org/10.1212/NXI.0000000000200078

Ejemplares similares

The role of diet in multiple sclerosis onset and course: results from a nationwide retrospective birth‐year cohort
por: Loonstra, Floor C., et al.
Publicado: (2023)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Association of Arachidonic Acid–Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis
por: Broos, Jelle Y., et al.
Publicado: (2023)

Adipokines in multiple sclerosis patients are related to clinical and radiological measures
por: Loonstra, Floor C., et al.
Publicado: (2022)

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis
por: Lam, KH, et al.
Publicado: (2020)

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?
por: Dekker, Iris, et al.
Publicado: (2019)

Repair what is lost: Neuroprotection through neural stem cells in progressive MS
por: Schoonheim, Menno M., et al.
Publicado: (2023)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
por: Coric, Danko, et al.
Publicado: (2017)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis
por: Coerver, Eline M. E., et al.
Publicado: (2022)

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes
por: Strijbis, Eva MM, et al.
Publicado: (2020)

COVID-19 in multiple sclerosis: The Dutch experience
por: Loonstra, Floor C, et al.
Publicado: (2020)

Serum Contactin-1 in CIDP: A Cross-Sectional Study
por: Wieske, Luuk, et al.
Publicado: (2021)

State Changes During Resting-State (Magneto)encephalographic Studies: The Effect of Drowsiness on Spectral, Connectivity, and Network Analyses
por: Strijbis, Eva M. M., et al.
Publicado: (2022)

Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS
por: Schoonhoven, Deborah N, et al.
Publicado: (2018)

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

Gray matter networks and cognitive impairment in multiple sclerosis
por: Rimkus, Carolina M, et al.
Publicado: (2018)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

11 Clinical Manifestations of Neuroaxonal Injury
por: Keleman, Audrey A., et al.
Publicado: (2023)

Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR
por: Noteboom, Samantha, et al.
Publicado: (2023)

Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis
por: Simon, Shira, et al.
Publicado: (2023)

Diabetes and Neuroaxonal Damage in Parkinson's Disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)

Predicting clinical progression in multiple sclerosis after 6 and 12 years
por: Dekker, I., et al.
Publicado: (2019)

The sequence of structural, functional and cognitive changes in multiple sclerosis
por: Dekker, Iris, et al.
Publicado: (2020)

The natural history of infantile neuroaxonal dystrophy
por: Altuame, Fadie D., et al.
Publicado: (2020)

Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis
por: Lam, Ka-Hoo, et al.
Publicado: (2023)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

Infantile Neuroaxonal Dystrophy: Diagnosis and Possible Treatments
por: Babin, Patricia L., et al.
Publicado: (2018)

Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method
por: Popescu, Veronica, et al.
Publicado: (2016)

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis
por: Dekker, Iris, et al.
Publicado: (2017)

Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis
por: Strik, Myrte, et al.
Publicado: (2022)

Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis
por: Nauta, Ilse M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_stcm410i67drc5fn4qeoamesig